Navigation Links
Japan Pharma Review: Outlook to 2017
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Japan Pharma Review: Outlook to 2017

http://www.reportlinker.com/p0968572/Japan-Pharma-Review-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Japan's pharmaceutical industry is in the midst of a defining period. The sector has evolved dramatically over the past decade, as companies attempt to gain ground on their Western peers in meeting the demands of global healthcare markets.Analysis of Japan Pharma's domestic and international competitive environmentAssess Japan Pharma's strategy for driving growth and extending its global reachWhile the top 10 companies in Japan Pharma are dominant within their domestic market, generating more than half of overall prescription pharma revenues in Japan, a range of factors have provided the impetus for companies to expand their global footprint.Evaluate the drivers and resistors of sales growth for the Japan Pharma peer set, both in its domestic market and overseasAssess Japan Pharma's strategic opportunities to bolster its performance

 

SCOPE OF ANALYSIS•PharmaVitae Explorer database

 

EXECUTIVE SUMMARY•Key findings

•Japan Pharma's expanding global footprint - Closing the gap on Big Pharma

- Japan still a stronghold for domestic players

- US revenues set for 25% decline; focus shifting towards areas of unmet need

- Takeda – leading the trend in globalization

- External strategies employed to reinforce long-term growth

 

 

HISTORICAL EVOLUTION OF JAPAN PHARMA•Introduction - Corporate evolution of Japan Pharma

 

JAPAN PHARMA DOMESTIC MARKET ANALYSIS: FOCUS ON JAPAN•Key domestic growth drivers - Aging Japanese population

- Japan Pharma focus shifting towards chronic disease areas

 

•Key domestic growth resistors - Domestic outlook is positive overall despite downward pressures

 

JAPAN PHARMA INTERNATIONAL MARKET ANALYSIS: FOCUS ON GLOBALIZATION•International drivers and resistors - Japan Pharma geographical positioning

- Overseas products offer greater likelihood of reaching blockbuster revenues

- Upsurge in overseas acquisitions by Japan Pharma

 

•Financial catalysts of Japan Pharma's international position - Strong balance sheet provides springboard for M&A

- Currency fluctuations have greatly enhanced the overseas purchasing power of Japan Pharma

 

•Product portfolio dynamics - Positive impact of externally sourced products on sales performance

- Pipelines are increasingly focused on international development

- Shift towards oncology drug development

- Expiry impact – generic erosion in the US is trigger for M&A

- Shift away from the blockbuster model

 

APPENDIX•References

•Exchange rates

 

TABLES

•Table: Datamonitor's established pharmaceutical company coverage, 2012

•Table: Top 10 companies in Japan Pharma, sales ($m), 2005–17

•Table: Exchange rates, 2012

 

FIGURES

•Figure: The PharmaVitae Explorer

•Figure: Evolution of Japan Pharma's corporate strategy

•Figure: Top 10 prescription pharmaceutical companies in Japan in 2011 (Japan FY2012)

•Figure: Global prescription pharmaceutical sales, split by region (% of total sales)

•Figure: Summary of drivers and resistors in the domestic Japanese market

•Figure: Leading pharmaceutical companies' prescription pharmaceutical sales in Japan, 2011

•Figure: Japanese population distributed by age (millions of people)

•Figure: Japan Pharma domestic growth forecast by therapy area

•Figure: Generic usage by volume in major markets

•Figure: Japan Pharma domestic sales by age of drug (in years)

•Figure: Japan Pharma combined sales forecast in domestic market

•Figure: Summary of drivers and resistors impacting Japan Pharma globalization strategy

•Figure: Global pharmaceutical sales by company, 2011

•Figure: Geographical focus of Japan Pharma vs Global Pharma, 2011

•Figure: Overseas sales of Japan Pharma, 2005–11

•Figure: Japan Pharma overseas market focus, 2011

•Figure: Japan Pharma's top 20 products by sales, 2011

•Figure: Japan Pharma's cash vs debt, 2006–11

•Figure: Historical exchange rate of yen vs US dollar, euro, and pound, January 2007 to January 2012

•Figure: Overseas sales of Japan Pharma by product source, 2005–17

•Figure: Japan Pharma global clinical development pipeline, Phase I to registration

•Figure: Japan Pharma global clinical development pipeline by therapy area

•Figure: Japan Pharma expiry sales forecast, 2011–17

•Figure: Overseas sales of top 10 Japan Pharma companies by drug value

 

Companies Mentioned

Abbott Laboratories, Actelion Ltd, Allergan, Inc., Amgen, Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Biogen Idec, Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Limited, F. Hoffmann-La Roche Ltd, Forest Laboratories, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Les Laboratoires Servier, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Shire plc

 

To order this report:

Pharmaceutical Industry: Japan Pharma Review: Outlook to 2017

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
2. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
3. Pharmaceutical Supply Chain in Japan - Periodic Drug Price Revisions by National Health Insurance Increase Competition and Squeeze Profit Margins
4. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
5. CPhI Japan Triumphs in the Prestigious AEO Excellence Awards
6. Accuray Rolls Out Comprehensive Customer Service Program in Japan
7. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
8. Empire Genomics Chooses Funakoshi as Japan Distributor
9. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
10. FDAnews announces Third Annual Pharmaceutical Labeling Summit
11. JHP Pharmaceuticals to Produce Lyophilized Biologic for International Late-Phase Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Lilly and Company (NYSE: LLY ) today announced that ... regimen patent would not presently be infringed by Actavis marketing ... Italy and Spain ... solution.  --> --> ... that Lilly,s patent would be indirectly infringed by Actavis marketing ...
(Date:2/12/2016)... februari 2016 AAIPharma Services Corp./Cambridge ... van productie en ontwikkeling op maat voor ... een uitbreiding aan van steriele vul- en ... Charleston, SC . Substantiële ... recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... 12, 2016 --> ... Chronic Inflammation Global Clinical Trials Review, H2, 2015 ... global clinical trials landscape along with top level ... Country (G7 & E7), Trial Status, Trial Phase, ... top companies involved and enlists all trials (Trial ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, DDS, ... dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from ... their time and skills to help hundreds of uninsured and underinsured people receive much-needed ...
(Date:2/12/2016)... ... 2016 , ... Homeowners now have a next generation tool ... leading brand of building products, has improved upon its industry-best array of home ... of the ColorView® Exterior Style and Color Selector. Created expressly for the iPad®, ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... creating explosive growth in the field of long term care. With that, says ... for well-trained healthcare professionals in administrative roles in long term care environments. His ...
(Date:2/12/2016)... ... , ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of ... is licensed under Dignity Health Arizona General Hospital , which opened last year ... ensure our new freestanding emergency room delivers the highest quality care to Mesa and ...
Breaking Medicine News(10 mins):